Genentech Logo

Scientist Profile

Morgan Sheng

Vice President: Neuroscience
 
"As a neuroscientist with a medical background, I am inspired to understand how the brain works from the level of molecule to cognitive behavior, and to tackle serious brain diseases based on understanding of biological mechanisms."
 

I started at Genentech in September 2008. Prior to that, I spent 14 years as a faculty member in the Boston area - first at Massachusetts General Hospital/Harvard Medical School and then at Massachusetts Institute of Technology (MIT), where I was Professor of Neuroscience. Before I got into research I was a practicing physician in London, U.K. So I have seen human disease from two sides - as a scientist investigating basic mechanisms and as a medical doctor treating patients.

I came to Genentech because I believe this company is best equipped to translate our increasing knowledge of the basic causes of disease into effective new treatments for serious brain disorders. I am energized by the people at Genentech, who have the right combination of know-how, creativity and motivation to make a difference for patients.

See More

 
 
My Focus

At Genentech we are committed to building a world-class Neuroscience Research program that will discover new drugs to treat major diseases of the nervous system. Not only are neurological and psychiatric conditions common and debilitating, but for many of them, there is no satisfactory treatment, a case in point being Alzheimer's disease. To meet these unmet needs, a current focus area of research is neurodegenerative disorders.

Much of my research is focused on brain "synapses," the tiny structures by which cells in the brain (neurons) contact and communicate with each other. Groups of neurons link together via synapses to form a functional "circuit." An emerging realization is that many diseases of the brain result from defective development or aberrant function of synapses, leading to circuit malfunction. For instance, Alzheimer's disease is characterized by severe loss of synapses in the brain as well as death of neurons. I believe that if we can understand the molecules that control the number, structure and function of synapses, we should be able to discover novel ways to treat many important neuropsychiatric illnesses.

See More

 
My Interests

Diseases of the nervous system have long afflicted large numbers of the world's population - in total, they inflict a terrible burden on patients, caregivers and society. Yet the treatment of most neurological and psychiatric disorders remains a huge unmet need. A big problem has been our ignorance of how the brain works normally and how it goes wrong in disease. In recent years, however, advances in neuroscience research are revealing the detailed mechanisms of neuronal and brain function, thus opening up promising new avenues for the treatment of neurodegeneration, psychosis, mood disorder, autism, pain and other conditions.

As a neuroscientist with a medical background, I am inspired to understand how the brain works from the level of molecule to cognitive behavior, and to tackle serious brain diseases based on understanding of biological mechanisms. These goals can only be achieved by the combined effort of many scientists, because neuroscience, perhaps more than any other branch of biology, is a multidisciplinary endeavor. Genentech - with its culture of scientific excellence, innovation and teamwork - offers a particularly stimulating and productive environment for realizing breakthrough drug discoveries. That is why I am excited to be here, working hard with my colleagues in Neuroscience Research.

See More

 
Publications & Recognition
  • Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization in hippocampal neurons.
  • Cell 2010; (in press).
  • Li Z, Jo J, Jia J-M, Lo S-C, Whitcomb DJ, Jiao S, Cho K, Sheng M.
  • Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines.
  • Cell 2010 Feb 19; 140(4): 567-78.
  • Bingol B, Wang CF, Arnott D, Cheng D, Peng J, Sheng M.
  • Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132.
  • Neuron 2010 Feb 11; 65(3): 373-84.
  • Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M.
 
View All Publications & Recognition
 
  • Genentech
  • Vice President, Neuroscience
  • 2008-Present
  • Massachusetts Institute of Technology (MIT)
  • Menicon Professor, Department of Brain and Cognitive Sciences, and Department of Biology
  • 2001-2008
  • MIT
  • Investigator, Howard Hughes Medical Institute
  • 2001-2008
  • MIT
  • Principal Investgator, RIKEN-MIT Neuroscience Research Center
  • 2001-2008
  • Massachusetts General Hospital (MGH) and Harvard Medical School, Boston
  • Associate Professor, Department of Neurobiology
  • 1998-2001
  • MGH
  • Assistant Investigator, and Associate Investigator, Howard Hughes Medical Institute
  • 1994-2001
  • MGH and Harvard Medical School, Boston
  • Assistant Professor, Department of Neurobiology
  • 1994-1998
  • University of California, San Francisco
  • Neuroscience, Postdoctoral Fellow
  • 1990-1994
  • Harvard University
  • Molecular Genetics, Ph.D.
  • 1986-1990
  • General Medicine London, U.K.
  • Internship and Residency, M.R.C.P.
  • 1982-1986
  • London University, U.K., Guys Hospital Medical School
  • Medicine, M.B.B.S.
  • 1979-1982
  • University of Oxford, U.K., Corpus Christi College
  • Physiology, B.A.
  • 1976-1979
Publications & Recognition
  • Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization in hippocampal neurons.
  • Cell 2010; (in press).
  • Li Z, Jo J, Jia J-M, Lo S-C, Whitcomb DJ, Jiao S, Cho K, Sheng M.
  • Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines.
  • Cell 2010 Feb 19; 140(4): 567-78.
  • Bingol B, Wang CF, Arnott D, Cheng D, Peng J, Sheng M.
  • Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132.
  • Neuron 2010 Feb 11; 65(3): 373-84.
  • Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M.
  • Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity.
  • J Neurosci 2008; 28(26): 6583-91.
  • Seeburg DP, Sheng M.
  • Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity.
  • Neuron 2008; 58(4): 571-83.
  • Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DT, Sheng M.
  • Smaller Dendritic Spines, Weaker Synaptic Transmission but Enhanced Spatial Learning in Mice Lacking Shank1.
  • J Neurosci 2008; 28(7): 1697-708.
  • Hung AH, Futai K, Sala C, Valtschanoff J, Ryu J, Woodworth M, Kidd FL, Sung CC, Miyakawa T, Bear MF, Weinberg FJ, Sheng M.
  • Synaptic accumulation of PSD-95 and synaptic function regulated by phosphorylation of serine-295 of PSD-95.
  • Neuron 2007; 56(3): 488-502.
  • Kim MJ, Futai K, Jo J, Hayashi Y, Cho K, Sheng M.
  • The Postsynaptic Architecture of Excitatory Synapses: A More Quantitative View.
  • Annu Rev Biochem 2007; 76: 823-47.
  • Sheng M, Hoogenraad CC.
  • A critical role for myosin IIb in dendritic spine morphology and synaptic function.
  • Neuron 2006; 49(2): 175-82.
  • Ryu J, Liu L, Wong TP, Wu DC, Burette A, Weinberg R, Wang YT, Sheng M.
  • Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking.
  • Neuron 2005; 46(5): 745-60.
  • Kim MJ, Dunah AW, Wang YT, Sheng M.
  • GRIP1 controls dendrite morphogenesis by regulating EphB receptor trafficking.
  • Nat Neurosci 2005; 8(7): 906-15.
  • Hoogenraad CC, Milstein AD, Ethell IM, Henkemeyer M, Sheng M.
  • Structure and different conformational states of native AMPA receptor complexes.
  • Nature 2004; 433: 545-549.
  • Nakagawa T, Cheng Y, Ramm E, Sheng M*, Walz T. (* corresponding author).
  • Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions.
  • Neuron 2004; 44: 453-67.
  • Nakagawa T, Futai K, Lashuel HA, Lo I, Okamoto K, Walz T, Hayashi Y, Sheng M.
  • Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons.
  • Neuron 2004; 43: 221-36.
  • Lee SH, Simonetta A, Sheng M.
  • Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry.
  • J Biol Chem 2004; 279: 21003-11.
  • Peng J, Kim MJ, Cheng D, Duong DM, Gygi SP, Sheng M.
  • The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses.
  • Cell 119: 873-87.
  • Li Z, Okamoto K, Hayashi Y, Sheng M.
  • Targeted Protein Degradation and Synapse Remodeling by an Inducible Protein Kinase.
  • Science 2003; 302: 1368-73.
  • Pak DTS, Sheng M.
  • Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR2.
  • Nature 2003; 424: 677-681.
  • Passafaro M, Nakagawa T, Sala C, Sheng M.
  • Clathrin Adaptor AP2 and NSF Interact with Overlapping Sites of GluR2 and Play Distinct Roles in AMPA Receptor Trafficking and Hippocampal LTD.
  • Neuron 2002; 36: 661-674.
  • Lee SH, Liu L, Wang YT, Sheng M.
  • Regulation of dendritic spine morphology and synaptic function by shank and homer.
  • Neuron 2001; 31: 115-130.
  • Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M.
  • Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization.
  • Nature Neurosci 2000; 3: 1282-1290.
  • Lin JW, Ju W, Foster K, Lee, SH, Wang YT, Sheng M.
  • Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2.
  • Nature 2000; 404: 298-302.
  • Hsueh Y-P, Wang T-F, Yang F-C, Sheng M.
  • Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin.
  • Neuron 1999; 23: 569-582.
  • Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, Worley PF, Sheng M.
  • Competitive binding of a-actinin and calmodulin to NMDA receptors.
  • Nature 1997; 385: 439-442.
  • Wyszynski M, Lin J, Rao A, Beggs A, Nigh E, Craig AM, Sheng M.
  • Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ.
  • Cell 1996; 85: 1067-1076.
  • Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R.
  • Clustering of Shaker-type K+ channels by interaction with a family of membrane associated guanylate kinases.
  • Nature 1995; 378: 85-88.
  • Kim E, Niethammer M, Rothschild A, Jan YN, Sheng M.
  • Changing subunit composition of heteromeric NMDA receptors during development of rat cortex.
  • Nature 1994; 368, 144-147.
  • Sheng M, Cummings J, Roldan LA, Jan YN, Jan, LY.